- Home
- GMED vs RVMD Comparison
GMED vs RVMD Comparison
Compare GMED & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMED
- RVMD
- Stock Information
- Founded
- GMED 2003
- RVMD 2014
- Country
- GMED United States
- RVMD United States
- Employees
- GMED N/A
- RVMD N/A
- Industry
- GMED Medical/Dental Instruments
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GMED Health Care
- RVMD Health Care
- Exchange
- GMED Nasdaq
- RVMD Nasdaq
- Market Cap
- GMED 9.6B
- RVMD 8.7B
- IPO Year
- GMED 2012
- RVMD 2020
- Fundamental
- Price
- GMED $72.53
- RVMD $37.29
- Analyst Decision
- GMED Buy
- RVMD Strong Buy
- Analyst Count
- GMED 13
- RVMD 13
- Target Price
- GMED $97.09
- RVMD $67.77
- AVG Volume (30 Days)
- GMED 1.4M
- RVMD 1.2M
- Earning Date
- GMED 05-06-2025
- RVMD 05-07-2025
- Dividend Yield
- GMED N/A
- RVMD N/A
- EPS Growth
- GMED N/A
- RVMD N/A
- EPS
- GMED 0.75
- RVMD N/A
- Revenue
- GMED $2,519,355,000.00
- RVMD N/A
- Revenue This Year
- GMED $8.56
- RVMD N/A
- Revenue Next Year
- GMED $6.73
- RVMD $153.09
- P/E Ratio
- GMED $98.21
- RVMD N/A
- Revenue Growth
- GMED 60.62
- RVMD N/A
- 52 Week Low
- GMED $49.33
- RVMD $29.55
- 52 Week High
- GMED $94.93
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- GMED 37.78
- RVMD 42.92
- Support Level
- GMED $72.00
- RVMD $37.42
- Resistance Level
- GMED $76.99
- RVMD $39.59
- Average True Range (ATR)
- GMED 2.12
- RVMD 1.32
- MACD
- GMED 0.48
- RVMD 0.05
- Stochastic Oscillator
- GMED 44.94
- RVMD 29.10
About GMED Globus Medical Inc.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.